These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11060733)

  • 21. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
    Harenberg J; Zokai K; Piazolo L; Fenyvesi T; Jörg I
    Semin Thromb Hemost; 2002 Aug; 28(4):379-82. PubMed ID: 12244485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model.
    Scherstén F; Wahlund G; Björnheden T; Carlsson S; Mattsson C; Grip L
    Blood Coagul Fibrinolysis; 2003 Apr; 14(3):235-41. PubMed ID: 12695745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
    Wolzt M; Levi M; Sarich TC; Boström SL; Eriksson UG; Eriksson-Lepkowska M; Svensson M; Weitz JI; Elg M; Wåhlander K
    Thromb Haemost; 2004 Jun; 91(6):1090-6. PubMed ID: 15175794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
    Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
    Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation.
    Koestenberger M; Cvirn G; Gallistl S; Baier K; Leschnik B; Muntean W
    J Thromb Thrombolysis; 2004 Aug; 18(1):5-10. PubMed ID: 15744547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
    Gustafsson D; Elg M
    Thromb Res; 2003 Jul; 109 Suppl 1():S9-15. PubMed ID: 12818629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
    Koestenberger M; Cvirn G; Gallistl S; Muntean W
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
    Johansson LC; Andersson M; Fager G; Gustafsson D; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):475-84. PubMed ID: 12739985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
    Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
    Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
    Sarich TC; Teng R; Peters GR; Wollbratt M; Homolka R; Svensson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):485-92. PubMed ID: 12739986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.
    Linder R; Frebelius S; Jansson K; Swedenborg J
    Blood Coagul Fibrinolysis; 2003 Feb; 14(2):139-46. PubMed ID: 12632023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition.
    Koestenberger M; Gallistl S; Cvirn G; Roschitz B; Rehak T; Leschnik B; Muntean W
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):131-7. PubMed ID: 15091000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombin inhibition with melagatran does not attenuate renal ischaemia-reperfusion injury in rats.
    Nitescu N; Grimberg E; Ricksten SE; Marcussen N; Guron G
    Nephrol Dial Transplant; 2007 Aug; 22(8):2149-55. PubMed ID: 17405786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
    Eriksson H; Eriksson UG; Frison L; Hansson PO; Held P; Holmström M; Hägg A; Jonsson T; Lapidus L; Leijd B; Stockelberg D; Säfwenberg U; Taghavi A; Thorsén M
    Thromb Haemost; 1999 Mar; 81(3):358-63. PubMed ID: 10102460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
    Clement B; Lopian K
    Drug Metab Dispos; 2003 May; 31(5):645-51. PubMed ID: 12695354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
    Klement P; Carlsson S; Rak J; Liao P; Vlasin M; Stafford A; Johnston M; Weitz JI
    J Thromb Haemost; 2003 Mar; 1(3):587-94. PubMed ID: 12871470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT).
    Cvirn G; Cimenti C; Kutschera J; Ferstl U; Wagner T; Muntean W; Jurgens G; Gallistl S; Koestenberger M
    Eur J Pediatr; 2007 May; 166(5):427-31. PubMed ID: 17047995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.